Progress in Prostate Cancer: A Focus on PARP Inhibitors

CE / CME

Progress in Prostate Cancer: A Focus on PARP Inhibitors
Credits Available
Physician Assistants: maximum of 1.50 hours of AAPA Category 1 CME credits Registered Nurses: 1.50 Nursing contact hours, includes 1.50 hour of pharmacology credit

Released: August 17, 2022

Expiration: August 16, 2023

Pretest

Progress
1 2
Course Completed
1.
Which of the following patients with prostate cancer should receive genetic testing to identify whether they are a candidate for PARP inhibitor therapy?
2.
Tom is a 69-year-old patient with metastatic castration-resistant prostate cancer with progression on enzalutamide after previous therapy with docetaxel. His tumor has a somatic BRCA2 mutation. Which of the following PARP inhibitors would you recommend as appropriate therapy for Tom’s BRCA2-mutated tumor? 
3.
Which of these is a recommended strategy for patients starting treatment with a PARP inhibitor?